Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Aldous MB, Grayston JT, Wang SP, Foy HM (1992) Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966–1979. J Infect Dis 166: 646–649
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997
Ariyo AA, Haan M, Tangen CM et al. (2000) Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 102: 1773–1779
Assmann G; Cullen P; Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105: 310–315
Bergmann KE, Mensink GBM (1999) Körpermaße und Übergewicht. Gesundheitswesen 61 Sonderheft 2: S115–S120
Blair SN, Jackson AS (2001) Physical fitness and activity as separate heart disease risk factors: a meta-analysis. Med Sci Sports Exerc 33: 762–764
Broeckel U, Hengstenberg C, Mayer B et al. (2002) A comprehensive linkage analysis for myocardial infarction and its related risk factors. Nature Genetics 30: 210–214
Brown BG, Zhao XQ, Chait A et al. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583–1592
Bucher HC, Griffi th LE, Guyatt GH (1999) Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 19: 187–195
Calle EE, Thun MJ, Petrelli JM et al. (1999) Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341: 1097–1105
Carluccio E, Tommasi S, Bentivoglio M et al. (2000) Prognostic value of left ventricular hypertrophy and geometry in patients with a first, uncomplicated myocardial infarction. Int J Cardiol 2000 74: 177–183
Carney RM, Blumenthal JA, Stein PK et al. (2001) Depression, heart rate variability, and acute myocardial infarction. Circulation 104: 2024–2028
Chiasson JL, Josse RG, Gomis R and the STOP-NIDDM Trail Research Group (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072–2077
Chiasson JL, Josse RG, Gomis R and the STOP-NIDDM Trial Research Group (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486–494
Collins R, Peto R, MacMahon S et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335: 827–838
Dahlof B, Devereux RB, Kjeldsen SE et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003
Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102: 1082–1085
DeBacker G, Ambrosioni E, Borch-Johnsen K et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24: 1601–1610
Diez Roux AV, Merkin SS, Arnett D et al. (2001) Neighborhood of residence and incidence of coronary heart disease. New Engl J Med 345: 99–106
Downs JR, Clearfield M, Weis S et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615–1622
Dunn FG; Pringle SD (1993) Sudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy. J Hypertens 11: 1003–1010
Erkens JA, Klungel OH, Herings RM et al. (2002) Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients. Eur Heart Journal 23: 1575–1579
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Adult Treatment Panel (ATP) III. JAMA 285: 2486–2497
Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr 68: 899–917
Franz IW, Tonnesmann U, Muller JF (1998) Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am J Hypertens 11: 631–639
Fuchs CS, Stampfer MJ, Colditz GA et al. (1995) Alcohol consumption and mortality among women. New N Engl J Med 332: 1245–1250
Gaede P, Vedel P, Larsen N et al. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–393
Gerstein H (2002) Dysglycemia: a key cardiovascular risk factor. Sem Vasc Med 2: 165–174
Glassman AH, O’Connor CM, Califf RM et al. (2002) Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288: 701–709
Gould AL, Rossouw JE, Santanello NC et al. (1998) Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97: 946–952
Grady D, Herrington D, Bittner V et al. (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288: 49–57
Grayston JT (1992) Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 15: 757–761
Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF (2003) Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Ann Intern Med 138: 383–389
Guidelines Committee (2003) European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 21: 1011–1053
Haffner SM (1998) The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocrine Rev 19: 583–592
Haffner SM, Lehto S, Ronnemaa T et al. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229–234
Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. 351: 1755–1762
Harrap SB, Dominiczak AF, Fraser R (1996) Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 93: 1148–1154
Hauner H, Hamann A, Husemann B et al. (2002) Evidenzbasierte Leitlinie — Adipositas. Prävention und Therapie der Adipositas. www.adipositas-gesellschaft.de/Leitlinien/Evidenzbasierte-Leitlinien-Adipositas.pdf. Gesehen 16 Dez 2004
Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 highrisk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22
Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005–2016
Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. Cardiovasc Risk. 3: 213–219
Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015–2022
Humphrey LL, Chan BK, Sox HC (2002) Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 137: 273–284
Hurt RD, Sachs DP, Glover ED et al. (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337: 1195–1202
Klingbeil AU, Schneider M, Martus P et al. (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115: 41–46
Knowler WC, Barrett-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403
Kohler C, Temelkova-Kurktschiev T, Schaper F et al. (1999) Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes. Dtsch Med Wochenschr 124: 1057–1061
Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423–1430
Levy D, Salomon M, D’Agostino RB et al. (1994) Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90: 1786–1793
Lewington S, Clarke R, Qizilbash N et al. (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913
Liebson PR, Grandits G, Prineas R et al. (1993) Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation 87: 476–486
Liem A, Reynierse-Buitenwerf GH, Zwinderman AH et al. (2003) Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 41: 2105–2113
Manson JE, Hu FB, Rich-Edwards JW et al. (1999) CHA prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 341: 650–658
Meier CR, Derby LE, Jick SS et al. (1999) Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 281: 427–431
Mensink GBN (1999) Körperliche Aktivität. Gesundheitswesen 61: S126–S131
Muhlestein JB, Horne BD, Carlquist JF et al. (2000) Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 102: 1917–1923
Muldoon MF, Manuck SB, Mendelsohn AB et al. (2001) Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 322: 11–15
NCEP (2002) National Cholesterol Education Program. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the NCEP, Final Report. Circulation 106: 3144–3412
Neal B, MacMahon S, Chapman N and the Blood Pressure Lowering Treatment Trialists’ Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 356:1955–1964
Nelson HD, Humphrey LL, Nygren P et al. (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288: 872–881
Pedersen TR, Olsson AG, Faergeman O et al. (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97: 1453–1460
Peeters A, Barendregt JJ, Willekens F et al. (2003) Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 138: 24–32
Penninx BW, Guralnik JM, Mendes de Leon CF et al. (1998) Cardiovascular events and mortality in newly and chronically depressed persons 70 years of age. Am J Cardiol 81: 988–994
Peters AL, Davidson MB, Schriger DL, Hasselblad VA (1996) Clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 276: 1246–1252
Pradhan AD, Manson JE, Rossouw JE (2002) Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA 288: 980–987
Prasad A, Zhu J, Halcox JP et al. (2002) Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 106: 184–190
Qiao Q, Pyorala K, Pyorala M et al. (2002) Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 23: 1267–1275
Renaud SC, Gueguen R, Schenker J, d’Houtaud A (1998) Alcohol and mortality in middle-aged men from eastern France. Epidemiology 9: 184–188
Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103: 1813–1818
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 336: 973–979
Ridker PM, Rifai N, Clearfield M et al. (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New Engl J Med 344: 1959–1965
Ridker PM, Rifai N, Rose L et al. (2002) Comparison of C-reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557–1565
Rifai N, Buring JE, Lee IM, Manson JE, Ridker PM (2002) Is C-reactive protein specific for vascular disease in women? Ann Intern Med 136: 529–533
Rimm EB, Williams P, Fosher K et al. (1999) Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 319: 1523–1528
Robins SJ, Collins D, Wittes JT (2001) Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285: 1585–1591
Rossouw JE, Anderson GL, Prentice RL et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333; http://www.whi.org/url
Rupprecht HJ, Blankenberg S, Bickel C et al. (2001) Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 104: 25–31
Sacks FM, Svetkey LP, Vollmer WM et al. (2001) Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344: 3–10
Sacks FM, Tonkin AM, Craven T et al. (2002) Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 105: 1424–1428
Schnyder G, Roffi M, Pin R et al. (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345: 1593–1600
Schunkert H, Hense HW, Holmer SR et al. (1994) Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 330: 1634–1638
Sdringola S, Patel D, Gould KL (2001) High prevalence of myocardial perfusion abnormalities on positron emission tomography in asymptomatic persons with a parent or sibling with coronary artery disease. Circulation 103: 496–501
Sesso HD, Paffenbarger RS Jr, Lee IM (2000) Physical activity and coronary heart disease in men: The Harvard Alumni Health Study. Circulation 102: 975–980
Sesso HD, Lee IM, Gaziano JM et al. (2001) Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Ciruclation 104: 393–398
Sever PS, Dahlof B, Poulter NR et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149–1158
SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265: 3255–3264
Shepherd J, Cobbe SM, Ford I (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301–1307
Silagy C, Lancaster T, Stead L et al. (2002) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 4: CD000146
Singer DE, Nathan DM, Anderson KM et al. (1992) Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 41: 202–208
Smieja M, Gnarpe J, Lonn E et al. (2003) Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 107: 251–257
Solomon CG, Hu FB, Stampfer MJ et al. (2000) Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus. Circulation. 102: 494–499
Stamler J, Wentworth D, Neaton JD (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenes of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823–2828
Stewart RAH, North FM, West TM et al. (2003) Depression and cardiovascular morbidity and mortality. Eur Heart J 24: 2027–2037
Stone AF, Mendall MA, Kaski JC et al. (2002) Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106: 1219–1223
Thompson PD, Buchner D, Pina IL et al. (2003) Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 107: 3109–3116
Thun MJ; Peto R; Lopez AD et al. (1997) Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 337: 1705–1714
UKPDS (1998a) United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.Circulation317: 703–713
UKPDS (1998b) UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853
UKPDS (1998c) UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865
Verdecchia P, Schillaci G, Borgioni C et al. (1998) Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97: 48–54
Verdecchia P, Carini G, Circo A et al. (2001) Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 38: 1829–1835
Verma S, Wang CH, Li SH et al. (2002) A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106: 913–919
Vijan S, Hayward RA (2003) Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 138: 593–602
Wald DS, Law M, Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325: 1202–1209
Wannamethee SG, Shaper AG, Walker M (2000) Physical activity and mortality in older men with diagnosed coronary heart disease. Circulation 102: 1358–1363
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Schneider, C.A. (2006). Kardiovaskuläre Risikofaktoren und deren therapeutische Beeinflussung. In: Erdmann, E. (eds) Klinische Kardiologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-29425-2_1
Download citation
DOI: https://doi.org/10.1007/3-540-29425-2_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-23742-6
Online ISBN: 978-3-540-29425-2
eBook Packages: Medicine (German Language)